Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53

Saved in:
Bibliographic Details
Main Authors: Jacques Fantini, Fodil Azzaz, Anaïs Aulas, Henri Chahinian, Nouara Yahi
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-025-07762-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849238523112062976
author Jacques Fantini
Fodil Azzaz
Anaïs Aulas
Henri Chahinian
Nouara Yahi
author_facet Jacques Fantini
Fodil Azzaz
Anaïs Aulas
Henri Chahinian
Nouara Yahi
author_sort Jacques Fantini
collection DOAJ
format Article
id doaj-art-2b73cd01a9114d439ece13bcf27ecb4b
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-2b73cd01a9114d439ece13bcf27ecb4b2025-08-20T04:01:35ZengNature PortfolioScientific Reports2045-23222025-07-011511310.1038/s41598-025-07762-4Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53Jacques Fantini0Fodil Azzaz1Anaïs Aulas2Henri Chahinian3Nouara Yahi4Aix Marseille Univ, INSERM UA16Aix Marseille Univ, INSERM UA16AmyPoreAix Marseille Univ, INSERM UA16Aix Marseille Univ, INSERM UA16https://doi.org/10.1038/s41598-025-07762-4
spellingShingle Jacques Fantini
Fodil Azzaz
Anaïs Aulas
Henri Chahinian
Nouara Yahi
Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53
Scientific Reports
title Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53
title_full Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53
title_fullStr Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53
title_full_unstemmed Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53
title_short Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53
title_sort correction preclinical assessment of a ganglioside targeted therapy for parkinson s disease with the first in class adaptive peptide amyp53
url https://doi.org/10.1038/s41598-025-07762-4
work_keys_str_mv AT jacquesfantini correctionpreclinicalassessmentofagangliosidetargetedtherapyforparkinsonsdiseasewiththefirstinclassadaptivepeptideamyp53
AT fodilazzaz correctionpreclinicalassessmentofagangliosidetargetedtherapyforparkinsonsdiseasewiththefirstinclassadaptivepeptideamyp53
AT anaisaulas correctionpreclinicalassessmentofagangliosidetargetedtherapyforparkinsonsdiseasewiththefirstinclassadaptivepeptideamyp53
AT henrichahinian correctionpreclinicalassessmentofagangliosidetargetedtherapyforparkinsonsdiseasewiththefirstinclassadaptivepeptideamyp53
AT nouarayahi correctionpreclinicalassessmentofagangliosidetargetedtherapyforparkinsonsdiseasewiththefirstinclassadaptivepeptideamyp53